Celera, 180 Kimball Way, South San Francisco, CA 94080, USA.
Abstract:
The structure-based design of potent and selective urokinase-type plasminogen activator (uPA) inhibitors with 4-aminoarylamidine or 4-aminoarylguanidine S1 binding groups, is described.